PR Newswire Association L.L.C.

News agencies

Blueprint Medicines Publishes Preclinical Proof-of-Concept Data on Promising New Therapy for Genomically Defined Hepatocellular Carcinoma

Blueprint Medicines announced the publication of preclinical proof-of-concept data on a promising new therapy for patients with genomically defined hepatocellular carcinoma (HCC). The company's lead drug, BLU-554, demonstrated superior efficacy compared to sorafenib, the only systemic treatment currently approved for HCC patients. BLU-554 is a selective, covalent inhibitor